medicationControlledSchedule IV (US)Prescription only (US)Armodafinil (Nuvigil) is FDA-approved for excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift-work disorder, and is federally controlled as Schedule IV in the United States
ArmodafinilBenefits, Dosage & Interactions
Also known as: Nuvigil
Armodafinil (Nuvigil) is a prescription wakefulness-promoting agent approved for excessive sleepiness from narcolepsy, obstructive sleep apnea and shift work disorder. It is the longer-lasting R-enantiomer of modafinil, so a given milligram amount produces higher and more sustained afternoon blood levels.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Quick answer
Armodafinil (Nuvigil) is a prescription wakefulness-promoting agent approved for excessive sleepiness from narcolepsy, obstructive sleep apnea and shift work disorder. It is the longer-lasting R-enantiomer of modafinil, so a given milligram amount produces higher and more sustained afternoon blood levels. It is a Schedule IV controlled substance and carries a warning for serious rash including Stevens-Johnson syndrome.
- Brand name
- Nuvigil
- Relationship to modafinil
- The purified R-enantiomer — longer-acting half
- Approved for
- Narcolepsy, OSA-related sleepiness, shift work disorder
- Schedule
- DEA Schedule IV controlled substance
- Half-life
- Roughly 15 hours — higher late-day levels than modafinil
- Serious warning
- Rare severe rash (SJS/TEN); stop at first sign of rash
Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.
Plasma half-life
~15 h
Typical timing
morning
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- 150–250 mg once daily has been the studied and labeled dose range for excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift-work disorder, as summarized in the cited pharmacology review[1][3]
- Frequency
- Once daily, typically in the morning or, for shift-work disorder, roughly an hour before the work shift[1][3]
Reported for Armodafinil in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Armodafinil entry is written from. Each number matches an inline marker above.
- [1]ArmodafinilGarnock-Jones KP, Dhillon S, Scott LJ · CNS Drugs · 2009 · Peer-reviewed · PMID 19689169
- [2]Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndromeHirshkowitz M, Black JE, Wesnes K, Niebler G, Arora S, Roth T · Respiratory Medicine · 2007 · Peer-reviewed · PMID 16908126
- [3]Armodafinil (Nuvigil) for wakefulnessThe Medical Letter on Drugs and Therapeutics · 2010 · Reference database · PMID 20697340
How to track Armodafinil doses
Tracking Armodafinil well takes four fields and a habit. Here is what to record so the log is still useful in three months.
- 1
Add the dose and unit
Log Armodafinil with its dose in mg so totals stay comparable over time — including days when you split the dose or skip it.
- 2
Set the time of day and food rule
Typical timing is morning. Reminders fire at that time and can export to your calendar.
- 3
Check it against the rest of the stack
Run Armodafinil through the interaction checker against everything else in the routine — supplements, peptides, hormones and prescriptions — before it becomes a daily habit.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 15 h, effects and timing shifts show up over days rather than instantly. Review Armodafinil alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg
- Time of day
- Taken / skipped / delayed
- Any side effects or notable changes
References & Evidence
Sources on this page that document Armodafinil dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Armodafinil?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Armodafinil, commonly known by its brand name Nuvigil, is a prescription medication categorized as a wakefulness-promoting agent. It is a single-isomer compound of modafinil, specifically the R-enantiomer, which is believed to be responsible for the majority of modafinil's pharmacologic activity. Armodafinil is primarily prescribed to improve wakefulness in adults who experience excessive sleepiness associated with certain sleep disorders. These include narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD). While it helps manage excessive daytime sleepiness, it does not cure these underlying sleep disorders. Armodafinil is classified as a Schedule IV controlled substance due to its potential for abuse and dependence, as noted by the U.S. Drug Enforcement Administration (DEA). Its use requires careful medical supervision.
Armodafinil has a half-life of approximately 15 hours, which contributes to its long-lasting wakefulness-promoting effects. It is typically taken once daily in the morning, or approximately an hour before a work shift for those with shift work sleep disorder, as described in FDA prescribing information. It can be taken with or without food. The medication works by affecting certain neurotransmitters in the brain involved in the sleep-wake cycle. While effective for its approved indications, it is not intended for mild fatigue or to replace adequate sleep. Its off-label uses are not supported by the same level of evidence as its on-label uses, and any off-label consideration should be discussed comprehensively with a healthcare provider.
What does the research say about Armodafinil?
Tap a section to expand.
The precise mechanism of action of armodafinil is not fully understood, but it is believed to involve multiple neurotransmitter systems in the brain. Unlike traditional stimulants, armodafinil does not appear to act directly as a general dopaminergic agonist. Instead, its wakefulness-promoting effects are thought to be mediated by its ability to indirectly modulate several key pathways involved in alertness and arousal.
According to DrugBank and FDA prescribing information, armodafinil is thought to selectively inhibit the reuptake of dopamine by binding to the dopamine transporter (DAT). This leads to increased extracellular dopamine levels in certain brain regions, particularly those involved in wakefulness. However, its effects are distinct from those of typical psychostimulants, which tend to have more widespread dopaminergic effects. Armodafinil's more targeted action may contribute to its lower potential for euphoria and dependence compared to traditional stimulants.
Furthermore, armodafinil is believed to influence other neurotransmitter systems. It may activate the histaminergic system in the hypothalamus, which plays a critical role in promoting wakefulness. There is also evidence suggesting it can modulate orexin (hypocretin) pathways, which are central to regulating the sleep-wake cycle. Orexin neurons are known to be deficient in narcolepsy with cataplexy. While armodafinil does not directly stimulate orexin production, it may enhance the effects of existing orexin. It does not appear to primarily work through widespread adrenergic pathways, which differentiates it from many traditional stimulants. Its interactions with serotonin and norepinephrine systems are also complex and contribute to its overall pharmacological profile, according to research cited by PubChem.
Source for this section: Sources for How does Armodafinil work?: Jumps to this entry in the sources and references list at the end of the page.
Armodafinil is primarily used to address excessive daytime sleepiness associated with specific sleep disorders, as detailed by Mayo Clinic and FDA prescribing information. The main benefits include:
* **Improved Wakefulness in Narcolepsy:** For individuals with narcolepsy, armodafinil helps reduce sudden and uncontrollable episodes of sleep, promoting sustained wakefulness throughout the day. This can significantly improve daily functioning and quality of life.
* **Reduced Sleepiness in Obstructive Sleep Apnea (OSA):** Even with appropriate primary treatment (such as CPAP therapy), some people with OSA continue to experience residual excessive daytime sleepiness. Armodafinil can help mitigate this persistent sleepiness, aiding in alertness during waking hours.
* **Enhanced Alertness in Shift Work Sleep Disorder (SWSD):** For those whose work schedules conflict with their natural circadian rhythms, leading to difficulty staying awake during shifts and sleeping during off-shift hours, armodafinil can improve wakefulness during scheduled work periods. This can boost performance and reduce the risk of errors or accidents associated with drowsiness.
* **Improved Cognitive Function (indirectly):** By reducing excessive sleepiness, armodafinil can indirectly lead to improved concentration, attention, and executive function in affected individuals, as chronic sleepiness can impair these cognitive abilities.
It is crucial to understand that armodafinil treats the symptom of excessive sleepiness but does not cure the underlying sleep disorder. Its effectiveness in improving objective measures of sleepiness has been demonstrated in clinical trials, as summarized by reviews on Examine.com.
Armodafinil's efficacy for its approved indications—excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD)—is well-established through multiple randomized, placebo-controlled clinical trials. Data from these trials are summarized in FDA prescribing information and by organizations like Mayo Clinic.
For **narcolepsy**, studies have consistently shown that armodafinil improves measures of wakefulness and reduces subjective sleepiness. Participants treated with armodafinil demonstrated significant improvements on objective tests such as the Maintenance of Wakefulness Test (MWT) and subjective scales like the Epworth Sleepiness Scale (ESS) compared to placebo. An NIH ODS review highlights these findings, indicating sustained wakefulness throughout the day.
In **obstructive sleep apnea (OSA)**, armodafinil has been shown to be effective in patients who experience residual excessive daytime sleepiness despite receiving primary therapy for their OSA (e.g., continuous positive airway pressure (CPAP)). Clinical trials have reported improvements in MWT scores and ESS scores, helping these individuals maintain alertness during the day. The benefits are supplementary to, not a replacement for, primary OSA treatment, as noted by MedlinePlus.
For **shift work sleep disorder (SWSD)**, armodafinil has been found to improve wakefulness and alertness during scheduled night or early morning work shifts, and to reduce sleepiness during commuting periods. Studies have used various measures including MWT, ESS, and patient-reported outcomes to demonstrate these effects. Cochrane reviews, when available for related compounds like modafinil, often reflect similar conclusions regarding wakefulness promotion.
It is important to note that while some individuals may use armodafinil off-label for other conditions, the evidence supporting these uses is typically less robust or not officially recognized by regulatory bodies. Any such use should be thoroughly discussed with a healthcare professional.
Like all medications, armodafinil can cause side effects, although not everyone experiences them. The most commonly reported side effects, as described in FDA prescribing information and by sources like Mayo Clinic, tend to be mild to moderate and may include:
* Headache
* Nausea
* Dizziness
* Insomnia (especially if taken too late in the day)
* Anxiety
* Dry mouth
* Diarrhea or constipation
* Nervousness
* Upper respiratory tract infection
Less common but more serious side effects can occur and require immediate medical attention. These include:
* **Severe Rash and Hypersensitivity Reactions:** Life-threatening rashes, including Stevens-Johnson Syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported, primarily in patients treated with modafinil (the parent compound) but also with armodafinil. These reactions can begin as a rash but progress to severe skin and organ damage. Discontinue armodafinil at the first sign of a rash or any allergic reaction.
* **Psychiatric Symptoms:** New or worsening psychiatric symptoms such as anxiety, mania, hallucinations, delusions, suicidal ideation, and psychosis have been reported. Patients with a history of psychiatric conditions may be at increased risk.
* **Cardiovascular Effects:** Increases in blood pressure and heart rate have been observed. Patients with pre-existing cardiovascular conditions should be monitored carefully.
* **Persistent Sleepiness:** In rare cases, individuals may experience persistent sleepiness or fatigue, especially if the dose is too low or the underlying sleep disorder is not adequately managed.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Before starting armodafinil, it is crucial to be aware of several important warnings and precautions, as detailed by DrugBank and FDA prescribing information. These are in place to ensure safe and effective use of the medication:
* **Severe Rash and Hypersensitivity:** Potentially life-threatening rash and other serious hypersensitivity reactions, including angioedema and anaphylaxis, have been observed. If a rash occurs, armodafinil should be discontinued immediately and not restarted. Patients should be informed about these risks.
* **Psychiatric Symptoms:** Armodafinil can cause new onset or exacerbation of psychiatric symptoms, including anxiety, depression, psychosis, mania, and suicidal thoughts. Patients with a history of psychosis, depression, or mania should be closely monitored. Discontinue if such symptoms develop.
* **Cardiovascular Effects:** Increases in blood pressure and heart rate, which can be clinically significant, have been reported. Caution is advised when administering armodafinil to patients with a history of hypertension, cardiovascular disease, or recent myocardial infarction or unstable angina. Regular blood pressure and heart rate monitoring is recommended.
* **Persistent Sleepiness:** Armodafinil does not eliminate the underlying cause of excessive sleepiness. Patients should be advised that their ability to engage in activities requiring complete mental alertness may still be impaired, especially if they have residual sleepiness or are also taking other sedating medications. Patients should exercise caution when operating hazardous machinery or driving until they are reasonably certain that armodafinil does not adversely affect their ability to do so.
* **Drug Abuse and Dependence:** Armodafinil is a Schedule IV controlled substance due to its potential for abuse and dependence. Patients with a history of drug or alcohol abuse should be monitored closely.
* **Effects on Steroidal Contraceptives:** Armodafinil may reduce the effectiveness of steroidal contraceptives (e.g., birth control pills) for approximately one month after discontinuation due to induction of hepatic enzymes. Alternative or concomitant methods of contraception are recommended for women of childbearing potential.
* **Multiorgan Hypersensitivity Reactions (DRESS):** Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported, characterized by fever, rash, lymphadenopathy, and involvement of other organ systems (e.g., hepatitis, nephritis, eosinophilia). This can be fatal. Discontinue armodafinil immediately if DRESS is suspected.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Armodafinil is contraindicated in certain situations where its use could be harmful. These contraindications are based on known risks and are outlined in FDA prescribing information and by DrugBank:
* **Hypersensitivity:** Individuals with a known hypersensitivity to armodafinil, modafinil, or any of their inactive ingredients should not use this medication. This includes patients who have developed a rash after taking modafinil or armodafinil.
* **History of Cardiovascular Conditions:** Patients with a history of left ventricular hypertrophy, ischemic ECG changes, mitral valve prolapse with a history of symptoms leading to stimulant use, or other serious cardiovascular conditions may have increased risks. While not an absolute contraindication for all, the risks often outweigh the benefits, and alternative treatments should be considered.
Patients should always inform their healthcare provider of their full medical history and all current medications to ensure armodafinil is appropriate and safe for them. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Care must be taken when combining armodafinil with other medications or substances, as interactions can alter the effectiveness of armodafinil or the co-administered drugs, or increase the risk of adverse effects. Consult FDA prescribing information and resources like MedlinePlus.
* **Hormonal Contraceptives:** Armodafinil can induce CYP3A4/5 enzyme activity in the liver, which can significantly reduce the plasma concentration and effectiveness of hormonal contraceptives (e.g., birth control pills, patches, rings, implants). Women of childbearing potential should use alternative or barrier methods of contraception during treatment with armodafinil and for one month after discontinuing it.
* **CYP3A4/5 Substrates:** Medications metabolized by the CYP3A4/5 enzyme may have their efficacy reduced when taken with armodafinil. Examples include cyclosporine, certain benzodiazepines (e.g., midazolam, triazolam), and some calcium channel blockers (e.g., amlodipine, verapamil). Dose adjustments or monitoring may be necessary.
* **CYP2C19 Substrates:** Armodafinil can inhibit CYP2C19 activity, potentially increasing the systemic exposure of drugs primarily metabolized by this enzyme. Examples include omeprazole, lansoprazole, clomipramine, and phenytoin. Increased monitoring for side effects or dose adjustments of these medications may be required.
* **MAO Inhibitors (MAOIs):** Concurrent use of armodafinil with MAOIs is generally not recommended due to potential additive pressor effects (increased blood pressure). This combination should be avoided due to the theoretical risk of hypertensive crisis, as cautioned by DrugBank.
* **Warfarin:** Armodafinil can increase the anticoagulant effect of warfarin by inhibiting its metabolism, leading to a higher risk of bleeding. Close monitoring of INR (International Normalized Ratio) and warfarin dose adjustments are essential if these medications are used together.
* **Alcohol and Central Nervous System (CNS) Depressants:** While interactions have not been systematically evaluated, it is generally recommended to avoid alcohol or use it cautiously with armodafinil. Concurrent use of CNS depressants may counteract armodafinil's wakefulness-promoting effects or lead to additive CNS side effects.
* **Other Stimulants:** Co-administration with other psychostimulants or wakefulness-promoting agents should be approached with caution due to the potential for additive effects on blood pressure, heart rate, and central nervous system stimulation.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Armodafinil is typically taken once daily. The specific timing depends on the condition being treated, as advised by FDA prescribing information and Mayo Clinic:
* **For Narcolepsy and Obstructive Sleep Apnea (OSA):** The usual recommendation is to take armodafinil as a single dose in the morning, usually around the time you awaken. This timing aims to promote wakefulness throughout the day and minimize the risk of insomnia at night, given its approximately 15-hour half-life.
* **For Shift Work Sleep Disorder (SWSD):** For individuals with SWSD, armodafinil should be taken approximately one hour prior to the start of their work shift. This helps to maximize alertness during the work period and reduce sleepiness. For example, if a night shift begins at 10 PM, the medication might be taken around 9 PM.
Armodafinil can be taken with or without food. Eating does not significantly alter its absorption kinetics. However, taking it too late in the day, especially for conditions other than SWSD where night work is involved, can lead to difficulty falling asleep at the usual bedtime. Adherence to the prescribed timing is important for optimizing efficacy and minimizing side effects like insomnia.
Source for this section: Sources for When should you take Armodafinil?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Armodafinil?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source pending | Specific pairs are checked against a licensed source; confirm with your provider. |
Frequently asked questions about Armodafinil
Armodafinil is a medication. It is also known as Nuvigil. The summary below is built from NIH monographs, PubChem chemical records and published trial literature rather than vendor copy.
Armodafinil is commonly discussed in the context of the goals discussed on its profile page. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Armodafinil, it is typically taken in the morning and its approximate half-life is 15 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Armodafinil carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Armodafinil is classified as a controlled substance in some jurisdictions, so legal status and prescribing rules apply. Stop use and contact a clinician if you experience unexpected symptoms.
Interaction risk for Armodafinil comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Armodafinil is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 15 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Armodafinil with no sign-up.
There is no single answer for Armodafinil plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Armodafinil with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 15 hours, once-daily dosing is the usual pattern for Armodafinil. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 15 hours, a single missed dose of Armodafinil usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Armodafinil the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Modafinil is a 50:50 mix of R- and S-enantiomers; the S half clears quickly while the R half persists. Armodafinil is the R half alone, so it produces a flatter, longer plasma curve with higher afternoon concentrations. Milligram amounts are therefore not interchangeable. This is educational information, not medical advice.
Armodafinil is classified as a wakefulness-promoting agent rather than a classical stimulant. Its exact mechanism is not fully established, but it involves weak dopamine transporter inhibition plus orexin and histamine pathway effects, producing less peripheral cardiovascular stimulation and less euphoria than amphetamines. This is educational information, not medical advice.
Yes — this is a clinically important one. Armodafinil induces CYP3A4, which can reduce the effectiveness of hormonal contraceptives. Labeling advises an alternative or additional method during treatment and for a month after stopping. This is educational information, not medical advice.
With a half-life around 15 hours, effects commonly extend 10–14 hours, which is why it is taken in the morning for daytime sleepiness or roughly an hour before a shift for shift work disorder. Late dosing frequently disrupts night-time sleep. This is educational information, not medical advice.
Which studies looked at Armodafinil?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Armodafinil(opens PubMed in a new tab)CNS Drugs · 2009 · PMID 19689169 · https://pubmed.ncbi.nlm.nih.gov/19689169/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 9690109(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/9690109
Verify at
Publisher search links for Armodafinil. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Armodafinil?
Plain-text summary, safe to quote verbatim:
Armodafinil (Nuvigil) is a prescription wakefulness-promoting agent approved for excessive sleepiness from narcolepsy, obstructive sleep apnea and shift work disorder. It is the longer-lasting R-enantiomer of modafinil, so a given milligram amount produces higher and more sustained afternoon blood levels.
Source: DoseRoutine — https://doseroutine.com/library/armodafinil
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Armodafinil — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/armodafinil
What compounds are similar to Armodafinil?
Others in the medication category or studied for the same goals.